Objective: Increased C3 has been related to body mass index (BMI) and insulin resistance, although there are not sufficient studies in subjects with morbid obesity. The purpose of this study was to evaluate the levels of C3 as a function of the BMI in subjects of both sexes, with severe, morbid and extreme obesity, and their possible relationship to insulin resistance or associated diseases such as diabetes, hypertension and dyslipidemia. Subjects: The study included a total of 316 patients (110 men and 206 women) with severe obesity (17.1%), morbid obesity (54.4%) and extreme obesity (28.4%), with an average BMI of 46.7077.37 kg/m 2 . Measurements: The glucose and insulin levels were determined baseline, and 2 h after a 75 g of oral glucose load. The homeostasis model of assessment for insulin resistance (HOMA-IR) was calculated. A lipid profile (total cholesterol, triglycerides, high-density lipoprotein cholesterol, apolipoprotein AI and apolipoprotein B100) was obtained and C3 levels determined by nephelometry. Results: When distributing the patients by quartiles of BMI, we found a progressive increase in the levels of C3, and no significant differences in the rest of analytical variables studied were found; the mean values of C3 were 127.78729.7 mg/dl. A significant correlation was found between C3 and the BMI (r ¼ 0.263, Po0.001), baseline insulin (r ¼ 0.237, P ¼ 0.001) and HOMA-IR (r ¼ 0.237, P ¼ 0.001). High blood pressure was found in 111 patients, type 2 diabetes in 74 patients and dyslipidemia in 139 cases. When distributing the levels of C3 according to the number of associated risk factors (hypertension, diabetes and dyslipidemia), we found significant differences between these patients and those who presented no associated diseases (Po0.01). Conclusion: A relationship between C3 and the progressive increase of BMI in subjects with severe, morbid or extreme obesity was established. This increase in C3 was closely related to insulin levels and the values for HOMA-IR. Furthermore, we also found an increase in C3 as more diseases related to insulin resistance, such as diabetes, hypertension and dyslipidemia, were associated with the obesity.
Introduction
The atherosclerotic process is now considered a chronic inflammatory process in which immune mechanisms with metabolic risk factors interact to initiate and develop vascular lesions. 1 The complement is a system of proteins connected on a functional level that interact with each other to provide many of the effector functions of humoral immunity and inflammation. The central component of the complement system is the C3 fraction, as all the pathways for activation of the system converge there.
Adipocytes are an important source of C3 production in addition to that produced in the liver in response to interleukin-1 and in activated macrophages. It has been shown that adipose tissue produces all the factors of the alternative pathway for activation of the complement; 2 recently, the gene expressions that code the proteins activating the complement system have been verified in human adipocytes. 3 There is a correlation between C3 levels and the majority of conventional risk factors, in both the general population 4 and in patients with cardiovascular disease, 5 and also a positive correlation was found between baseline insulin levels and C3 levels. 5 On the other hand, the concentrations of C3 positively correlate with both visceral and subcutaneous fat 2 and body mass index (BMI), [2] [3] in the general population of both sexes, although few studies have been exclusively carried out on a large number of subjects with severe or morbid obesity. It has been suggested that the insulin resistance that occurs in the majority of obese subjects would give rise to hyperproduction of cytokines in adipose tissue, thus conditioning a low-degree chronic inflammatory response responsible for activation of the complement system. This situation would finally be responsible for the metabolic complications observed in obesity. 6 This study considered an evaluation of the C3 levels as a function of the BMI in subjects of both sexes, with severe, morbid or extreme obesity and their possible relationship to insulin resistance or associated disorders such as diabetes, hypertension or dyslipidemia.
Patients and method
The study included patients with a BMI 435 kg/m All the subjects were asked about their previous history of hypertension, diabetes or cardiovascular disease. Subjects with a systolic blood pressure (SBP) of X140 mm Hg or diastolic of X90 mm Hg, or who were being treated with a hypotensive agent, were considered hypertense. 8 Subjects with a previous history of diabetes, fasting glycaemia X126 mg/dl on at least two occasions or glycaemia 2 h after an oral glucose load of X200 mg/dl, were considered diabetic. 9 Dyslipidemia was diagnosed when the figures for total cholesterol (TC) or triglycerides (TG) exceeded 200 mg/ dl, or the subjects were taking lipid-lowering drugs. The weight was determined without footwear and with light clothing using electronic scales with an approximation of 0.1 kg and a capacity of up to 200 kg. The height was measured with a stadiometer with an approximation of 0.5 cm. The BP was measured twice consecutively using a mercury sphygmomanometer fitted with a suitable sleeve, maintaining the subject in the seated position and at the end of the visit. The BMI was calculated by dividing the weight in kilograms by the square of the height in metres. The circumference of the waist was measured at the natural indentation between the 10th rib and the iliac crest and the circumference of the hips at the height of the major trochanter, using a metric tape with approximations of 0.5 cm.
Each subject's blood was sampled after 12 h fast for the measurements of serum lipids, lipoproteins and apolipoproteins, C3, insulin and plasma glucose concentrations. Insulin and glucose concentrations were also measured 2 h after oral glucose load of 75 g.
The blood samples were collected in serum separator tube (SST), BD vacutainer s tubes, which were immediately centrifuged at 41C for 10 min at 3000 r.p.m. The serum was aliquoted for making the different determinations on the same day of extraction: glucose, TC and TG by enzymatic method, 10, 11 and high-density lipoproteins (HDLs) by direct method 12 in a Beckman LX20 automated analyser. The intraseries coefficient of variation was o3.5% for all these determinations. The low-density lipoproteins (LDLs) were calculated using Friedewald's formula, 13 for values of triglycerides below 300 mg/dl. All other aliquots were frozen to À801C until later processing: apolipoprotein B (Apo B) and apolipoprotein A-I (Apo A-I) and the C3 fraction of the complement were determined by immunonephelometry (Behring Nephelometer II (BNII), Dade-Behring) 14, 15 (intra-assay coefficient of variation o5.5%), and insulin was determined by immunochemiluminescence method in an immulite DPC analyser (intra-assay coefficient of variation o4%). The insulin resistance was calculated from the Homeostasis Model Assessment (HOMA). 16 The statistics program SPSS version 11.0. was used for statistical analysis. The comparison between two groups was performed by Student's t-test and the comparison of several groups was made by analysis of variance (ANOVA) for one factor and Bonferroni's post-hoc analysis if there were differences between groups or the Kruskall-Wallis test when the variances were not homogeneous. Furthermore, the correlation between variables was verified using Spearman's correlation coefficient. All the tests used a confidence interval of 95% and differences were considered significant when Po0.05.
Results
The study analysed a total of 316 patients (110 men and 206 women). The anthropometric data, BP and analytical variables studied are shown in Table 1 . There were 54 patients Levels of C3 in patients with severe, morbid and extreme obesity A Hernández-Mijares et al presenting class II or severe obesity (17.1%), 172 presented class III or morbid obesity (54.4%) and 90 had class IV or extreme obesity (28.4%). When studying the distribution of sex-dependent anthropometric variables, statistically significant differences between men and women were found for all variables except age and BMI. There was a significant increase in the SBP (Po0.001) and the diastolic BP (Po0.05) in men compared with women. In the analytical determinations, the only significant differences between men and women were found in high-density lipoprotein cholesterol (HDL-c) and insulin at 2 h after the overload of glucose.
High BP was present in 111 patients (53 men and 58 women), and only four of them were treated. Type 2 diabetes was present in 74 patients (28 men and 46 women), in 55 cases with baseline glycaemia X126 mg/dl or taking hypoglycemic drugs (three patients) and in 19 cases only with glycaemia at 2 h after the overload of glucose X200 mg/dl (diabetes mellitus not known). Dyslipidemia was found in 139 cases (54 men and 85 women).
To check the influence of BMI on the analytical variables studied, the patients were distributed by quartiles of BMI (Q1: 33.14-41.05 kg/m Table 2 . There were significant differences for C3 between quartiles Q1-Q3-Q4 and Q2-Q3-Q4, but no differences between quartiles Q1 and Q2. No significant differences were found between the different quartiles for the other analytical variables studied. When distributing the levels of C3 depending on the number of associated disorders (hypertension, type 2 diabetes and dyslipidemia), significant differences were found between patients with only obesity, and those who had the obesity associated with one, or several of these disorders (ANOVA Po0.01) ( Table 3) . The relationship between C3 levels and the number of metabolic risk factors associated with obesity could not be explained by BMI, which does not differ between groups. Patients with more cardiovascular risk factors were older, but after age adjustment C3 levels were still different between groups (P ¼ 0.001).
Discussion
This study verified the significant increase in levels of C3 as the BMI increases in a population of subjects with severe, morbid and extreme obesity. It also revealed a significant correlation between the C3 values and parameters related to Levels of C3 in patients with severe, morbid and extreme obesity A Hernández-Mijares et al insulin resistance. On the other hand, a significant increase in C3 was found as each of these obese patients were associated with diseases such as hypertension, type 2 diabetes or dyslipidemia, all of which have underlying insulin resistance as the most important physiopathological pathway. Nowadays, adipose tissue is considered as being metabolically active, with a capacity for secretion of substances with autocrine and paracrine activities involved in the control of body weight and the homeostasis of glucose. 17 Human adipocytes are capable of synthesising and segregating three proteins components of the alternative complement pathway: C3, factor B and factor D (adipsin). 3, 18 The interaction of these three factors results in the generation of C3a, which is rapidly transformed into C3adesarg, also called acylationstimulating protein (ASP), which is synthesized and secreted by the adipocytes. 19 A positive correlation has been shown between C3 and ASP, although the latter is not correlated with the insulin levels in a baseline situation. 20 There are various lines of evidence where there seems to be an increase in C3 in situations of insulin resistance 20 and in ischemic cardiopathy; 4, 21, 22 furthermore, the presence of C3 was also verified on the arteriosclerotic plaque. 23 These findings indicate a hypothesis that one of the pathways by which the situation of insulin resistance could bring about an atherosclerotic process would be by means of an immunologic reaction in which C3 would be a very important factor. Values are expressed as mean7s.d. (95% confidence interval). There are significant differences among groups (ANOVA, P ¼ 0.006). After age adjustment differences among C3 levels still are statistically significant (P ¼ 0.001).
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There is little information in the literature about the relationship between C3 and obesity, although there are data on its relationship with BMI. In this regard, Muscari et al. 4 studied a general population of 1068 subjects (29.8%
with BMI 428 kg/m 2 ), finding a significant progressive increase in C3 levels in different BMI tertiles. In a recent study, Cianflone et al. 24 showed a significant increase in C3 in obese children without being associated with lipid disorders. Our study found that, in subjects of both sexes with severe, morbid and extreme obesity, there was an increase in C3 as the BMI increased, as well as a significant relationship between both parameters. This relationship had already been found in subjects with normal weight and in patients with mild or moderate obesity, 5 but there were no references in the literature to C3 levels in patients with such a high degree of obesity as those studied in this work. Our study showed a significant correlation between C3 and baseline insulin levels. This was very similar to the situation described by Muscari et al. 4 in a population whose mean BMI was approximately half that presented by the patients in our study. There was also a significant correlation between the levels of glycaemia (baseline and at 2 h after overload) and HOMA-IR and these results enable associating the situation of hyperinsulinism-insulin resistance with C3 levels in our obese patients. In the situation of insulin resistance presented in the majority of obese subjects, pro-inflammatory cytokines, especially interleukin 6 (IL6) and tumour necrosis factor alpha (TNFa), may play an important role in the insulin signal. 25 These cytokines inhibit tyrosine phosphorylation of the insulin receptor substrate-1. It has been shown that the adipocytes express TNFa and may produce 30-40% of the circulating levels of IL6, 26 the main regulator of C-reactive protein production in the liver. This hyperproduction of cytokines would condition a low-key chronic inflammatory response responsible for activation of the complement system, a situation that could contribute to the metabolic complications observed in obesity. 6 There is a correlation between C3 and the majority of conventional risk factors, both in the general population 4 as well as in patients with cardiovascular disease. 5 Increases in C3 were observed in patients with type 2 diabetes, 21, 22 hypertension 22 and dyslipidemia, 27 even in the absence of obesity. Our study revealed an additive effect of these diseases on C3. This effect remains statically significant after age adjustment.
In conclusion, we believe that this is the first study which has shown that there is a relationship between C3 and the progressive increase of BMI in subjects of both sexes with severe, morbid and extreme obesity. This increase in C3 is closely related to insulin levels and the values for HOMA-IR. Furthermore, we also found an increase in C3 as more diseases related to the insulin resistance such as type 2 diabetes, hypertension and dyslipidemia were associated with the obesity.
